Logo

Exiqon Completes Assays for Tacere, Pfizer RNAi Drug Alliance

Sep 17, 2009
Premium

Exiqon announced this week that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

As reported by RNAi News early last year, Tacere licensed its preclinical hepatitis C therapy TT-033 to Pfizer worldwide except in Asia, where Oncolys BioPharma has the drug's rights (see RNAi News, 1/10/2008).

According to Exiqon, the assays will be used to "assess critical performance points for the RNAi therapeutic in a preclinical setting."

Specific terms of the arrangement with Tacere were not disclosed.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Infectious Disease
Business News
Tacere Therapeutics
collaboration
HCV
RNAi
expressed RNAi
Pfizer
Qiagen
Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.